Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.24
-0.41 (-1.60%)
At close: Sep 26, 2025, 4:00 PM EDT
25.20
-0.04 (-0.16%)
After-hours: Sep 26, 2025, 4:45 PM EDT
Pacira BioSciences Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Pacira BioSciences stock ranges from a low of $18 to a high of $65. The average analyst price target of $32.4 forecasts a 28.37% increase in the stock price over the next year.
Price Target: $32.40 (+28.37%)
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +18.86% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +26.78% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +157.53% | Apr 8, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | -4.91% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +26.78% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
752.57M
from 700.97M
Increased by 7.36%
Revenue Next Year
828.37M
from 752.57M
Increased by 10.07%
EPS This Year
2.90
from -2.15
EPS Next Year
3.33
from 2.90
Increased by 14.54%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 780.7M | 871.5M | |||
| Avg | 752.6M | 828.4M | |||
| Low | 716.7M | 769.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.4% | 15.8% | |||
| Avg | 7.4% | 10.1% | |||
| Low | 2.2% | 2.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.11 | 3.70 | |||
| Avg | 2.90 | 3.33 | |||
| Low | 2.72 | 2.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 27.2% | |||
| Avg | - | 14.5% | |||
| Low | - | -4.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.